Skip to main content

Zai Lab Ltd

corporate_fare Company Profile

Zai Lab Ltd

ZLAB·NASDAQ·Life Sciences·CIK 0001704292

We are a patient-focused, innovative, commercial-stage, global biopharmaceutical company with a substantial presence in both Greater China and the United States. We focus on discovering, developing, and commercializing products for medical conditions with significant unmet needs in oncology, immunology, neuroscience, and infectious disease. Our experienced team has formed partnerships with leading global biopharmaceutical companies, resulting in a broad pipeline that includes multiple commercial products and multiple programs in late-stage clinical development. We also have an in-house research and development team with strong product discovery and translational research capabilities, and we are developing a pipeline of proprietary product candidates with global rights. Our mission is to be a leading global biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that improve the lives of patients. To achieve this, our strategy involves three pillars: accelerating medicines to patients by investing in research and development, expanding and strengthening our global and regional pipelines through internal discovery and collaborations, and continuing our commercial excellence and execution by increasing access to existing commercial products and improving efficiency as we prepare for new product launches or new indications for existing products.

Zai Lab Ltd (NASDAQ:ZLAB) is a publicly traded company in the Life Sciences sector. Wiseek monitors ZLAB SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Zai Lab President & COO Josh Smiley Departs; CEO Samantha Du Absorbs Responsibilities
  • Officer & Director Du Ying Files Intent to Sell Nearly $1M in Shares, Continuing Recent Pattern
  • Zai Lab Officer/Director Du Ying Files Intent to Sell $1.02 Million in Shares
  • Zai Lab Reports Mixed Q1 Financials with Revenue Decline, Improved Cash Burn, and Extensive Positive Pipeline Updates
  • Zai Lab Seeks Shareholder Approval for 10% Share Issuance & Repurchase Mandates, Details Related-Party Licensing Deal

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$460.16M
Net Income
-$175.54M
Diluted EPS
-$0.16
Op. Cash Flow
-$150.79M
Free Cash Flow
-$158.89M
Gross Profit
$269.64M
Operating Income
-$229.43M
Cash & Equivalents
$679.57M
Total Debt
$204.53M
Debt / Equity
0.29×
Net Margin
-38.1%
Shares Outstanding
1.11B sh
Source: 10-K · filed 2026-02-26 · accession 0001704292-26-000015
Browse all tickers starting with Z →
$17.08 +0.01% today
52-week range · as of 2026-05-21 $15.96 – $44.34
Market cap
$1.9B
Volume
1.3M (1.4× avg)
3-mo avg 905.9K
Live data · 2026-06-14 03:52 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ZLAB - Latest Insights

ZLAB
May 21, 2026, 5:18 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $19.10
Real-time Price: $17.08 info
Change: -$2.02 (-11%) info
Market Cap: $1.903B info
ZLAB
May 18, 2026, 11:34 AM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $18.95
Real-time Price: $17.08 info
Change: -$1.87 (-10%) info
Market Cap: $1.903B info
ZLAB
May 15, 2026, 9:49 AM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $21.22
Real-time Price: $17.08 info
Change: -$4.14 (-19%) info
Market Cap: $1.903B info
ZLAB
May 07, 2026, 6:09 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $20.99
Real-time Price: $17.08 info
Change: -$3.91 (-19%) info
Market Cap: $1.903B info
ZLAB
Apr 28, 2026, 7:16 AM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $21.99
Real-time Price: $17.08 info
Change: -$4.91 (-22%) info
Market Cap: $1.903B info
ZLAB
Apr 17, 2026, 7:12 AM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $23.49
Real-time Price: $17.08 info
Change: -$6.41 (-27%) info
Market Cap: $1.903B info
ZLAB
Feb 26, 2026, 7:08 AM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $19.30
Real-time Price: $17.08 info
Change: -$2.22 (-12%) info
Market Cap: $1.903B info
ZLAB
Feb 26, 2026, 7:04 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $19.20
Real-time Price: $17.08 info
Change: -$2.12 (-11%) info
Market Cap: $1.903B info